{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T21:54:50Z","timestamp":1788472490166,"version":"build-2803163510"},"reference-count":86,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T00:00:00Z","timestamp":1698710400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibiotics"],"abstract":"<jats:p>Certain classes of antibiotics show \u201cconcentration dependent\u201d antimicrobial activity; higher concentrations result in increased bacterial killing rates, in contrast to \u201ctime dependent antibiotics\u201d, which show antimicrobial activity that depends on the time that antibiotic concentrations remain above the MIC. Aminoglycosides and fluoroquinolones are still widely used concentration-dependent antibiotics. These antibiotics are not hydrolyzed by beta-lactamases and are less sensitive to the inoculum effect, which can be defined as an increased MIC for the antibiotic in the presence of a relatively higher bacterial load (inoculum). In addition, they possess a relatively long Post-Antibiotic Effect (PAE), which can be defined as the absence of bacterial growth when antibiotic concentrations fall below the MIC. These characteristics make them interesting complementary antibiotics in the management of Multi-Drug Resistant (MDR) bacteria and\/or (neutropenic) patients with severe sepsis. Global surveillance studies have shown that up to 90% of MDR Gram-negative bacteria still remain susceptible to aminoglycosides, depending on the susceptibility breakpoint (e.g., CLSI or EUCAST) being applied. This percentage is notably lower for fluoroquinolones but depends on the region, type of organism, and mechanism of resistance involved. Daily (high-dose) dosing of aminoglycosides for less than one week has been associated with significantly less nephro\/oto toxicity and improved target attainment. Furthermore, higher-than-conventional dosing of fluoroquinolones has been linked to improved clinical outcomes. Beta-lactam antibiotics are the recommended backbone of therapy for severe sepsis. Since these antibiotics are time-dependent, the addition of a second concentration-dependent antibiotic could serve to quickly lower the bacterial inoculum, create PAE, and reduce Penicillin-Binding Protein (PBP) expression. Inadequate antibiotic levels at the site of infection, especially in the presence of high inoculum infections, have been shown to be important risk factors for inadequate resistance suppression and therapeutic failure. Therefore, in the early phase of severe sepsis, effort should be made to optimize the dose and quickly lower the inoculum. In this article, the authors propose a novel concept of \u201cInoculum Based Dosing\u201d in which the decision for antibiotic dosing regimens and\/or combination therapy is not only based on the PK parameters of the patient, but also on the presumed inoculum size. Once the inoculum has been lowered, indirectly reflected by clinical improvement, treatment simplification should be considered to further treat the infection.<\/jats:p>","DOI":"10.3390\/antibiotics12111581","type":"journal-article","created":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T11:16:27Z","timestamp":1698750987000},"page":"1581","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Inoculum-Based Dosing: A Novel Concept for Combining Time with Concentration-Dependent Antibiotics to Optimize Clinical and Microbiological Outcomes in Severe Gram Negative Sepsis"],"prefix":"10.3390","volume":"12","author":[{"given":"Alwin","family":"Tilanus","sequence":"first","affiliation":[{"name":"Department of Infectious Diseases, Clinica Los Nogales, Calle 95 # 23-61, Bogota 110221, Colombia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Drusano","sequence":"additional","affiliation":[{"name":"Institute for Therapeutic Innovation, University of Florida, 6550 Sanger Road, Orlando, FL 32827, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,10,31]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"e1063","DOI":"10.1097\/CCM.0000000000005337","article-title":"Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021","volume":"49","author":"Evans","year":"2021","journal-title":"Crit. Care Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"R126","DOI":"10.1186\/cc9091","article-title":"Insufficient \u03b2-lactam concentrations in the early phase of severe sepsis and septic shock","volume":"14","author":"Taccone","year":"2010","journal-title":"Crit. Care"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1093\/cid\/ciu027","article-title":"DALI: Defining Antibiotic Levels in Intensive care unit patients: Are current beta-lactam antibiotic doses sufficient for critically ill patients?","volume":"58","author":"Roberts","year":"2014","journal-title":"Clin. Infect. Dis."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/S1473-3099(14)70036-2","article-title":"Individualised antibiotic dosing for patients who are critically ill: Challenges and potential solutions","volume":"14","author":"Roberts","year":"2014","journal-title":"Lancet Infect. Dis."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1097\/MCC.0000000000000229","article-title":"Pharmacokinetic\/pharmacodynamic considerations for the optimization of antimicrobial delivery in the critically ill","volume":"21","author":"Tsai","year":"2015","journal-title":"Curr. Opin. Crit. Care"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1177\/0310057X9302100206","article-title":"Aminoglycoside Volume of Distribution and Illness Severity in Critically Ill Septic Patients","volume":"21","author":"Marik","year":"1993","journal-title":"Anaesth. Intensive Care"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"S272","DOI":"10.1093\/infdis\/jiz651","article-title":"Association Between Pathophysiology and Volume of Distribution Among Patients With Sepsis or Septic Shock Treated With Imipenem: A Prospective Cohort Study","volume":"221","author":"Huang","year":"2020","journal-title":"J. Infect. Dis."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1186\/cc7774","article-title":"Bench-to-bedside review: Appropriate antibiotic therapy in severe sepsis and septic shock\u2014Does the dose matter?","volume":"13","author":"Pea","year":"2009","journal-title":"Crit. Care"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/nrmicro862","article-title":"Antimicrobial pharmacodynamics: Critical interactions of \u201cbug and drug\u201d","volume":"2","author":"Drusano","year":"2004","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2795","DOI":"10.1128\/AAC.05360-11","article-title":"Dosing Regimen Matters: The Importance of Early Intervention and Rapid Attainment of the Pharmacokinetic\/Pharmacodynamic Target","volume":"56","author":"Martinez","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e01323-17","DOI":"10.1128\/AAC.01323-17","article-title":"Dilution Factor of Quantitative Bacterial Cultures Obtained by Bronchoalveolar Lavage in Patients with Ventilator-Associated Bacterial Pneumonia","volume":"62","author":"Drusano","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1086\/516284","article-title":"Pharmacokinetic\/Pharmacodynamic Parameters: Rationale for Antibacterial Dosing of Mice and Men","volume":"26","author":"Craig","year":"1998","journal-title":"Clin. Infect. Dis."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"S89","DOI":"10.1086\/518137","article-title":"Pharmacokinetics and Pharmacodynamics of Antimicrobials","volume":"45","author":"Drusano","year":"2007","journal-title":"Clin. Infect. Dis."},{"key":"ref_14","first-page":"704","article-title":"Plazomicin: A New Aminoglycoside","volume":"70","author":"Saravolatz","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1097\/QCO.0000000000000012","article-title":"Aminoglycosides: How should we use them in the 21st century?","volume":"26","author":"Jackson","year":"2013","journal-title":"Curr. Opin. Infect. Dis."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"a027029","DOI":"10.1101\/cshperspect.a027029","article-title":"Aminoglycosides: An Overview","volume":"6","author":"Krause","year":"2016","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"377","DOI":"10.2165\/00003088-199427050-00005","article-title":"Pharmacokinetic Contributions to Postantibiotic Effects: Focus on Aminoglycosides","volume":"27","author":"Zhanel","year":"1994","journal-title":"Clin. Pharmacokinet."},{"key":"ref_18","first-page":"11","article-title":"The postantibiotic effect: A review of in vitro and in vivo data","volume":"25","author":"Zhanel","year":"1991","journal-title":"DCIP"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1093\/jac\/22.1.23","article-title":"Postantibiotic effect of aminoglycosides on Gram-negative bacteria evaluated by a new method","volume":"22","author":"Isaksson","year":"1988","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1093\/jac\/28.1.25","article-title":"Synergic post-antibiotic effect of amikacin in combination with beta-lactam antibiotics on gram-negative bacteria","volume":"28","author":"Isaksson","year":"1991","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1093\/jac\/27.suppl_C.29","article-title":"Pharmacodynamics of amikacin in vitro and in mouse thigh and lung infections","volume":"27","author":"Craig","year":"1991","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1093\/jac\/27.6.829","article-title":"Factors affecting duration of in-vivo postantibiotic effect for aminoglycosides against Gram-negative bacilli","volume":"27","author":"Fantin","year":"1991","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1128\/AAC.4.2.133","article-title":"Comparative In Vitro Activity of Three Aminoglycosidic Antibiotics: BB-K8, Kanamycin, and Gentamicin","volume":"4","author":"Yu","year":"1973","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1128\/AAC.9.3.440","article-title":"In Vitro Activity, Synergism, and Testing Parameters of Amikacin, with Comparisons to Other Aminoglycoside Antibiotics","volume":"9","author":"Kelly","year":"1976","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1128\/AAC.45.4.1287-1291.2001","article-title":"In Vitro and In Vivo Activities of Amikacin, Cefepime, Amikacin plus Cefepime, and Imipenem against an SHV-5 Extended-Spectrum beta-Lactamase-Producing Klebsiella pneumoniae Strain","volume":"45","author":"Szabo","year":"2001","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1093\/infdis\/155.1.93","article-title":"Clinical Response to Aminoglycoside Therapy: Importance of the Ratio of Peak Concentration to Minimal Inhibitory Concentration","volume":"155","author":"Moore","year":"1987","journal-title":"J. Infect. Dis."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1128\/AAC.43.3.623","article-title":"Optimizing Aminoglycoside Therapy for Nosocomial Pneumonia Caused by Gram-Negative Bacteria","volume":"43","author":"Kashuba","year":"1999","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.jgar.2017.09.019","article-title":"Impact of amikacin pharmacokinetic\/pharmacodynamic index on treatment response in critically ill patients","volume":"12","author":"Ruiz","year":"2018","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1128\/AAC.31.7.1054","article-title":"Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance","volume":"31","author":"Blaser","year":"1987","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1097\/FTD.0b013e31818b6b2f","article-title":"Suboptimal Aminoglycoside Dosing in Critically Ill Patients","volume":"30","author":"Rea","year":"2008","journal-title":"Ther. Drug Monit."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.ijantimicag.2014.09.006","article-title":"First-dose pharmacokinetics of aminoglycosides in critically ill haematological malignancy patients","volume":"45","author":"Blackburn","year":"2015","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ijantimicag.2015.02.009","article-title":"Standard dosing of amikacin and gentamicin in critically ill patients results in variable and subtherapeutic concentrations","volume":"46","author":"Roger","year":"2015","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2528","DOI":"10.1128\/AAC.01314-10","article-title":"Optimization of Aminoglycoside Therapy","volume":"55","author":"Drusano","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1128\/AAC.39.3.650","article-title":"Experience with a once-daily aminoglycoside program administered to 2,184 adult patients","volume":"39","author":"Nicolau","year":"1995","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"717","DOI":"10.7326\/0003-4819-124-8-199604150-00003","article-title":"Once-Daily Aminoglycoside Dosing in Immunocompetent Adults: A Meta-Analysis","volume":"124","author":"Hatala","year":"1996","journal-title":"Ann. Intern. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1128\/AAC.43.7.1549","article-title":"Prospective Evaluation of the Effect of an Aminoglycoside Dosing Regimen on Rates of Observed Nephrotoxicity and Ototoxicity","volume":"43","author":"Rybak","year":"1999","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1093\/clinids\/24.5.810","article-title":"Single Daily Dosing of Aminoglycosides in Immunocompromised Adults: A Systematic Review","volume":"24","author":"Hatala","year":"1997","journal-title":"Clin. Infect. Dis."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1093\/jac\/dkq451","article-title":"Once versus multiple daily dosing of aminoglycosides for patients with febrile neutropenia: A systematic review and meta-analysis","volume":"66","author":"Mavros","year":"2011","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1046\/j.1525-1497.1998.00224.x","article-title":"Risk factors for toxicity in elderly patients given aminoglycosides once daily","volume":"13","author":"Paterson","year":"1998","journal-title":"J. Gen. Intern. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1177\/0897190014546836","article-title":"Aminoglycoside-Induced Nephrotoxicity","volume":"27","author":"Wargo","year":"2014","journal-title":"J. Pharm. Pract."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.bcp.2014.05.018","article-title":"Entry of aminoglycosides into renal tubular epithelial cells via endocytosis-dependent and endocytosis-independent pathways","volume":"90","author":"Nagai","year":"2014","journal-title":"Biochem. Pharmacol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/ki.2010.337","article-title":"New insights into the mechanism of aminoglycoside nephrotoxicity: An integrative point of view","volume":"79","author":"Quiros","year":"2011","journal-title":"Kidney Int."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1093\/qjmed\/hcp143","article-title":"Gentamicin-associated acute kidney injury","volume":"102","author":"Selby","year":"2009","journal-title":"QJM"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1159\/000440867","article-title":"Acute Kidney Injury and Renal Recovery with the Use of Aminoglycosides: A Large Retrospective Study","volume":"131","author":"Paquette","year":"2015","journal-title":"Nephron"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"119","DOI":"10.2174\/138161207779313731","article-title":"Aminoglycoside-Induced Ototoxicity","volume":"13","author":"Selimoglu","year":"2007","journal-title":"Curr. Pharm. Des."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/0196-0709(89)90002-1","article-title":"Incidence of amikacin ototoxicity: A sigmoid function of total drug exposure independent of plasma levels","volume":"10","author":"Beaubien","year":"1989","journal-title":"Am. J. Otolaryngol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1128\/AAC.35.6.1070","article-title":"Evidence that amikacin ototoxicity is related to total perilymph area under the concentration-time curve regardless of concentration","volume":"35","author":"Beaubien","year":"1991","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"6337","DOI":"10.1128\/AAC.01050-15","article-title":"Amikacin Concentrations Predictive of Ototoxicity in Multidrug-Resistant Tuberculosis Patients","volume":"59","author":"Modongo","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1093\/clinids\/4.2.237","article-title":"Bactericidal synergism between beta-lactams and aminoglycosides: Mechanism and possible therapeutic implications","volume":"4","author":"Davis","year":"1982","journal-title":"Rev. Infect. Dis."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/0002-9343(86)90490-0","article-title":"Aminoglycosides plus beta-lactams against gram-negative organisms. Evaluation of in vitro synergy and chemical interactions","volume":"80","author":"Giamarellou","year":"1986","journal-title":"Am. J. Med."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1128\/CMR.05041-11","article-title":"Combination Therapy for Treatment of Infections with Gram-Negative Bacteria","volume":"25","author":"Tamma","year":"2012","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_52","first-page":"CD003344","article-title":"Beta lactam antibiotic monotherapy versus beta lactam-aminoglycoside antibiotic combination therapy for sepsis","volume":"2014","author":"Paul","year":"2014","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_53","first-page":"106","article-title":"In Vitro Activity of Carbapenems Alone and in Combination With Amikacin Against KPC-Producing Klebsiella pneumoniae","volume":"3","author":"Le","year":"2011","journal-title":"J. Clin. Med. Res."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"R53","DOI":"10.1186\/cc8945","article-title":"Revisiting the loading dose of amikacin for patients with severe sepsis and septic shock","volume":"14","author":"Taccone","year":"2010","journal-title":"Crit. Care"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.ijantimicag.2011.03.022","article-title":"Higher than recommended amikacin loading doses achieve pharmacokinetic targets without associated toxicity","volume":"38","author":"Luengo","year":"2011","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_56","first-page":"285","article-title":"Influence of sepsis on higher daily dose of amikacin pharmacokinetics in critically ill patients","volume":"17","author":"Mahmoudi","year":"2013","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1093\/jac\/dkv291","article-title":"Impact of 30 mg\/kg amikacin and 8 mg\/kg gentamicin on serum concentrations in critically ill patients with severe sepsis","volume":"71","author":"Roger","year":"2016","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/s13613-016-0211-z","article-title":"Impact of a high loading dose of amikacin in patients with severe sepsis or septic shock","volume":"6","author":"Allou","year":"2016","journal-title":"Ann. Intensive Care"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.ijantimicag.2017.11.009","article-title":"Higher versus standard amikacin single dose in emergency department patients with severe sepsis and septic shock: A randomised controlled trial","volume":"51","author":"Wauters","year":"2018","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s13613-020-00685-5","article-title":"Amikacin pharmacokinetic\/pharmacodynamic in intensive care unit: A prospective database","volume":"10","author":"Logre","year":"2020","journal-title":"Ann. Intensive Care"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"a025320","DOI":"10.1101\/cshperspect.a025320","article-title":"Topoisomerase Inhibitors: Fluoroquinolone Mechanisms of Action and Resistance","volume":"6","author":"Hooper","year":"2016","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1099\/jmm.0.000475","article-title":"Mechanisms of quinolone action and resistance: Where do we stand?","volume":"66","author":"Correia","year":"2017","journal-title":"J. Med. Microbiol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1021\/bi5000564","article-title":"Mechanism of Quinolone Action and Resistance","volume":"53","author":"Aldred","year":"2014","journal-title":"Biochemistry"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1007\/BF01966996","article-title":"The mode of action of quinolones: The paradox in activity of low and high concentrations and activity in the anaerobic environment","volume":"10","author":"Lewin","year":"1991","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Bush, N.G., Diez-Santos, I., Abbott, L.R., and Maxwell, A. (2020). Quinolones: Mechanism, Lethality and Their Contributions to Antibiotic Resistance. Molecules, 25.","DOI":"10.3390\/molecules25235662"},{"key":"ref_66","first-page":"63","article-title":"The post-antimicrobial suppressive effect of quinolone agents","volume":"13","author":"Neu","year":"1987","journal-title":"Drugs Exp. Clin. Res."},{"key":"ref_67","first-page":"58","article-title":"Post-antibiotic suppressive effect of ciprofloxacin against gram-positive and gram-negative bacteria","volume":"82","author":"Chin","year":"1987","journal-title":"Am. J. Med."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1093\/jac\/16.6.709","article-title":"Comparison of agar dilution, microtitre broth dilution and tube macrodilution susceptibility testing of ciprofloxacin against several pathogens at two different inocula","volume":"16","author":"Gombert","year":"1986","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1093\/jac\/20.5.639","article-title":"The inoculum effect with Gram-negative bacteria in vitro and in vivo","volume":"20","author":"Davey","year":"1987","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1080\/08820139.2020.1797778","article-title":"A Review of Immunomodulatory Effects of Fluoroquinolones","volume":"50","author":"Assar","year":"2021","journal-title":"Immunol. Investig."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1128\/AAC.37.5.1073","article-title":"Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients","volume":"37","author":"Forrest","year":"1993","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1128\/AAC.45.10.2793-2797.2001","article-title":"Pharmacodynamics of Fluoroquinolones against Streptococcus pneumoniae in Patients with Community-Acquired Respiratory Tract Infections","volume":"45","author":"Ambrose","year":"2001","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1086\/383320","article-title":"Relationship between Fluoroquinolone Area under the Curve:Minimum Inhibitory Concentration Ratio and the Probability of Eradication of the Infecting Pathogen, in Patients with Nosocomial Pneumonia","volume":"189","author":"Drusano","year":"2004","journal-title":"J. Infect. Dis."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.jcrc.2007.11.011","article-title":"Ciprofloxacin pharmacokinetics in critically ill patients: A prospective cohort study","volume":"23","author":"Polderman","year":"2008","journal-title":"J. Crit. Care."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1111\/j.1365-2125.2012.04337.x","article-title":"The ciprofloxacin target AUC: MIC ratio is not reached in hospitalized patients with the recommended dosing regimens: Ciprofloxacin concentrations in hospitalized patients","volume":"75","author":"Haeseker","year":"2013","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1093\/jac\/dkq211","article-title":"Support for higher ciprofloxacin AUC24\/MIC targets in treating Enterobacteriaceae bloodstream infection","volume":"65","author":"Zelenitsky","year":"2010","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1128\/AAC.26.5.678","article-title":"Postantibiotic effect of imipenem on Pseudomonas aeruginosa","volume":"26","author":"Bustamante","year":"1984","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/0732-8893(88)90072-7","article-title":"Comparison of the bactericidal activity of ciprofloxacin alone and in combination with selected antipseudomonal beta-lactam agents against clinical isolates of Pseudomonas aeruginosa","volume":"11","author":"Stratton","year":"1988","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"54","DOI":"10.2165\/00003495-199300453-00011","article-title":"Synergy and Antagonism of Fluoroquinolones with Other Classes of Antimicrobial Agents","volume":"45","author":"Neu","year":"1993","journal-title":"Drugs"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"2646","DOI":"10.1128\/AAC.00065-10","article-title":"The Combination of Meropenem and Levofloxacin Is Synergistic with Respect to both Pseudomonas aeruginosa Kill Rate and Resistance Suppression","volume":"54","author":"Louie","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.4065\/80.9.1146","article-title":"Ciprofloxacin vs. an Aminoglycoside in Combination With a \u03b2-Lactam for the Treatment of Febrile Neutropenia: A Meta-analysis of Randomized Controlled Trials","volume":"80","author":"Bliziotis","year":"2005","journal-title":"Mayo Clin. Proc."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"S42","DOI":"10.1086\/344653","article-title":"Prevention of Resistance: A Goal for Dose Selection for Antimicrobial Agents","volume":"36","author":"Drusano","year":"2003","journal-title":"Clin. Infect. Dis."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1093\/jac\/dkz226","article-title":"Inoculum effect of \u03b2-lactam antibiotics","volume":"74","author":"Lenhard","year":"2019","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"ofad305","DOI":"10.1093\/ofid\/ofad305","article-title":"Optimizing the Use of Beta-Lactam Antibiotics in Clinical Practice: A Test of Time","volume":"10","author":"Tilanus","year":"2023","journal-title":"Open Forum Infect. Dis."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1128\/AAC.35.1.117","article-title":"First-exposure adaptive resistance to aminoglycoside antibiotics in vivo with meaning for optimal clinical use","volume":"35","author":"Daikos","year":"1991","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1111\/jcpt.13301","article-title":"Loading dose and efficacy of continuous or extended infusion of beta-lactams compared with intermittent administration in patients with critical illnesses: A subgroup meta-analysis and meta-regression analysis","volume":"46","author":"Wu","year":"2021","journal-title":"J. Clin. Pharm. Ther."}],"container-title":["Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-6382\/12\/11\/1581\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:14:37Z","timestamp":1760130877000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-6382\/12\/11\/1581"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,31]]},"references-count":86,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2023,11]]}},"alternative-id":["antibiotics12111581"],"URL":"https:\/\/doi.org\/10.3390\/antibiotics12111581","relation":{},"ISSN":["2079-6382"],"issn-type":[{"value":"2079-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,31]]}}}